Others

Kodiak Sciences Announces Positive Interim Data from KSI-301 Phase 1b Clinical Trial, a Novel Anti-VEGF Biopolymer Conjugate for the Treatment of Wet AMD, Diabetic Eye Disease Retinal Venous Retention at the 2019 Annual Meeting of the American Retina Society

[ad_1] PALO ALTO, California, July 27, 2019 / PRNewswire / – Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in new treatments for the treatment of high-prevalence chronic retinal diseases, …

Read More »